Literature DB >> 29074950

Divergent evolutionary trajectories in transplanted tumor models.

Carlos Villacorta-Martin1, Amanda J Craig1, Augusto Villanueva1,2.   

Abstract

Human-derived tumor models are becoming popular in the context of personalized medicine, but a new study shows that these models could be less representative of primary tumors than previously thought, particularly when using late passages.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29074950     DOI： 10.1038/ng.3983

Source DB:  PubMed          Journal:  Nat Genet        ISSN： 1061-4036            Impact factor:   38.330


  9 in total

Review 1.  The future of patient-derived tumor xenografts in cancer treatment.

Authors:  Daniela Sia; Agrin Moeini; Ismail Labgaa; Augusto Villanueva
Journal:  Pharmacogenomics       Date:  2015-09-24       Impact factor: 2.533

2.  High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.

Authors:  Hui Gao; Joshua M Korn; Stéphane Ferretti; John E Monahan; Youzhen Wang; Mallika Singh; Chao Zhang; Christian Schnell; Guizhi Yang; Yun Zhang; O Alejandro Balbin; Stéphanie Barbe; Hongbo Cai; Fergal Casey; Susmita Chatterjee; Derek Y Chiang; Shannon Chuai; Shawn M Cogan; Scott D Collins; Ernesta Dammassa; Nicolas Ebel; Millicent Embry; John Green; Audrey Kauffmann; Colleen Kowal; Rebecca J Leary; Joseph Lehar; Ying Liang; Alice Loo; Edward Lorenzana; E Robert McDonald; Margaret E McLaughlin; Jason Merkin; Ronald Meyer; Tara L Naylor; Montesa Patawaran; Anupama Reddy; Claudia Röelli; David A Ruddy; Fernando Salangsang; Francesca Santacroce; Angad P Singh; Yan Tang; Walter Tinetto; Sonja Tobler; Roberto Velazquez; Kavitha Venkatesan; Fabian Von Arx; Hui Qin Wang; Zongyao Wang; Marion Wiesmann; Daniel Wyss; Fiona Xu; Hans Bitter; Peter Atadja; Emma Lees; Francesco Hofmann; En Li; Nicholas Keen; Robert Cozens; Michael Rugaard Jensen; Nancy K Pryer; Juliet A Williams; William R Sellers
Journal:  Nat Med       Date:  2015-10-19       Impact factor: 53.440

3.  Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts.

Authors:  J Graeme Hodgson; Ru-Fang Yeh; Amrita Ray; Nicholas J Wang; Ivan Smirnov; Mamie Yu; Sujatmi Hariono; Joachim Silber; Heidi S Feiler; Joe W Gray; Paul T Spellman; Scott R Vandenberg; Mitchel S Berger; C David James
Journal:  Neuro Oncol       Date:  2009-01-12       Impact factor: 12.300

Review 4.  Mouse models in oncoimmunology.

Authors:  Laurence Zitvogel; Jonathan M Pitt; Romain Daillère; Mark J Smyth; Guido Kroemer
Journal:  Nat Rev Cancer       Date:  2016-09-30       Impact factor: 60.716

5.  A community effort to assess and improve drug sensitivity prediction algorithms.

Authors:  James C Costello; Laura M Heiser; Elisabeth Georgii; Mehmet Gönen; Michael P Menden; Nicholas J Wang; Mukesh Bansal; Muhammad Ammad-ud-din; Petteri Hintsanen; Suleiman A Khan; John-Patrick Mpindi; Olli Kallioniemi; Antti Honkela; Tero Aittokallio; Krister Wennerberg; James J Collins; Dan Gallahan; Dinah Singer; Julio Saez-Rodriguez; Samuel Kaski; Joe W Gray; Gustavo Stolovitzky
Journal:  Nat Biotechnol       Date:  2014-06-01       Impact factor: 54.908

Review 6.  Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients.

Authors:  B Rubio-Viqueira; M Hidalgo
Journal:  Clin Pharmacol Ther       Date:  2008-11-12       Impact factor: 6.875

Review 7.  Patient-derived xenograft models: an emerging platform for translational cancer research.

Authors:  Manuel Hidalgo; Frederic Amant; Andrew V Biankin; Eva Budinská; Annette T Byrne; Carlos Caldas; Robert B Clarke; Steven de Jong; Jos Jonkers; Gunhild Mari Mælandsmo; Sergio Roman-Roman; Joan Seoane; Livio Trusolino; Alberto Villanueva
Journal:  Cancer Discov       Date:  2014-07-15       Impact factor: 39.397

8.  Patient-derived xenografts undergo mouse-specific tumor evolution.

Authors:  Uri Ben-David; Gavin Ha; Yuen-Yi Tseng; Noah F Greenwald; Coyin Oh; Juliann Shih; James M McFarland; Bang Wong; Jesse S Boehm; Rameen Beroukhim; Todd R Golub
Journal:  Nat Genet       Date:  2017-10-09       Impact factor: 38.330

9.  Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans.

Authors:  Timothy J Aitman; Rong Dong; Timothy J Vyse; Penny J Norsworthy; Michelle D Johnson; Jennifer Smith; Jonathan Mangion; Cheri Roberton-Lowe; Amy J Marshall; Enrico Petretto; Matthew D Hodges; Gurjeet Bhangal; Sheetal G Patel; Kelly Sheehan-Rooney; Mark Duda; Paul R Cook; David J Evans; Jan Domin; Jonathan Flint; Joseph J Boyle; Charles D Pusey; H Terence Cook
Journal:  Nature       Date:  2006-02-16       Impact factor: 49.962
  9 in total
  6 in total

Review 1.  How to Choose a Mouse Model of Breast Cancer, a Genomic Perspective.

Authors:  Matthew R Swiatnicki; Eran R Andrechek
Journal:  J Mammary Gland Biol Neoplasia       Date:  2019-06-21       Impact factor: 2.673

Review 2.  Genomic evolution of cancer models: perils and opportunities.

Authors:  Uri Ben-David; Rameen Beroukhim; Todd R Golub
Journal:  Nat Rev Cancer       Date:  2019-02       Impact factor: 60.716

Review 3.  Executable cancer models: successes and challenges.

Authors:  Matthew A Clarke; Jasmin Fisher
Journal:  Nat Rev Cancer       Date:  2020-04-27       Impact factor: 69.800

4.  Folate Repletion after Deficiency Induces Irreversible Genomic and Transcriptional Changes in Human Papillomavirus Type 16 (HPV16)-Immortalized Human Keratinocytes.

Authors:  Claudia Savini; Ruwen Yang; Larisa Savelyeva; Elke Göckel-Krzikalla; Agnes Hotz-Wagenblatt; Frank Westermann; Frank Rösl
Journal:  Int J Mol Sci       Date:  2019-03-04       Impact factor: 5.923

5.  Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns.

Authors:  Lidia Mateo; Miquel Duran-Frigola; Albert Gris-Oliver; Marta Palafox; Maurizio Scaltriti; Pedram Razavi; Sarat Chandarlapaty; Joaquin Arribas; Meritxell Bellet; Violeta Serra; Patrick Aloy
Journal:  Genome Med       Date:  2020-09-09       Impact factor: 11.117

Review 6.  Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma.

Authors:  Darel Martínez Bedoya; Valérie Dutoit; Denis Migliorini
Journal:  Front Immunol       Date:  2021-03-03       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.